Literature DB >> 28641794

Time-to-Furosemide Treatment and Mortality in Patients Hospitalized With Acute Heart Failure.

Yuya Matsue1, Kevin Damman2, Adriaan A Voors2, Nobuyuki Kagiyama3, Tetsuo Yamaguchi4, Shunsuke Kuroda5, Takahiro Okumura6, Keisuke Kida7, Atsushi Mizuno8, Shogo Oishi9, Yasutaka Inuzuka10, Eiichi Akiyama11, Ryuichi Matsukawa12, Kota Kato13, Satoshi Suzuki14, Takashi Naruke15, Kenji Yoshioka16, Tatsuya Miyoshi17, Yuichi Baba18, Masayoshi Yamamoto19, Koji Murai20, Kazuo Mizutani21, Kazuki Yoshida22, Takeshi Kitai23.   

Abstract

BACKGROUND: Acute heart failure (AHF) is a life-threatening disease requiring urgent treatment, including a recommendation for immediate initiation of loop diuretics.
OBJECTIVES: The authors prospectively evaluated the association between time-to-diuretic treatment and clinical outcome.
METHODS: REALITY-AHF (Registry Focused on Very Early Presentation and Treatment in Emergency Department of Acute Heart Failure) was a prospective, multicenter, observational cohort study that primarily aimed to assess the association between time to loop diuretic treatment and clinical outcome in patients with AHF admitted through the emergency department (ED). Door-to-furosemide (D2F) time was defined as the time from patient arrival at the ED to the first intravenous furosemide injection. Patients with a D2F time <60 min were pre-defined as the early treatment group. Primary outcome was all-cause in-hospital mortality.
RESULTS: Among 1,291 AHF patients treated with intravenous furosemide within 24 h of ED arrival, the median D2F time was 90 min (IQR: 36 to 186 min), and 481 patients (37.3%) were categorized as the early treatment group. These patients were more likely to arrive by ambulance and had more signs of congestion compared with the nonearly treatment group. In-hospital mortality was significantly lower in the early treatment group (2.3% vs. 6.0% in the nonearly treatment group; p = 0.002). In multivariate analysis, earlier treatment remained significantly associated with lower in-hospital mortality (odds ratio: 0.39; 95% confidence interval: 0.20 to 0.76; p = 0.006).
CONCLUSIONS: In this prospective multicenter, observational cohort study of patients presenting at the ED for AHF, early treatment with intravenous loop diuretics was associated with lower in-hospital mortality. (Registry focused on very early presentation and treatment in emergency department of acute heart failure syndrome; UMIN000014105).
Copyright © 2017 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  B-type natriuretic peptide; Get With the Guidelines; diuretics; emergency department; prognosis

Mesh:

Substances:

Year:  2017        PMID: 28641794     DOI: 10.1016/j.jacc.2017.04.042

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  48 in total

1.  Outpatient versus inpatient worsening heart failure: distinguishing biology and risk from location of care.

Authors:  Stephen J Greene; G Michael Felker; Javed Butler
Journal:  Eur J Heart Fail       Date:  2018-11-05       Impact factor: 15.534

2.  Diagnostic and prognostic value of plasma volume status at emergency department admission in dyspneic patients: results from the PARADISE cohort.

Authors:  Tahar Chouihed; Patrick Rossignol; Adrien Bassand; Kévin Duarte; Masatake Kobayashi; Déborah Jaeger; Sonia Sadoune; Aurélien Buessler; Lionel Nace; Gaetan Giacomin; Thibaut Hutter; Françoise Barbé; Sylvain Salignac; Nicolas Jay; Faiez Zannad; Nicolas Girerd
Journal:  Clin Res Cardiol       Date:  2018-10-28       Impact factor: 5.460

Review 3.  Diagnosis and Management of Acute Heart Failure in Sub-Saharan Africa.

Authors:  Alice Kidder Bukhman; Vizir Jean Paul Nsengimana; Mindy C Lipsitz; Patricia C Henwood; Endale Tefera; Shada A Rouhani; Damas Dukundane; Gene Y Bukhman
Journal:  Curr Cardiol Rep       Date:  2019-08-31       Impact factor: 2.931

4.  Adjuvant therapy in acute heart failure.

Authors:  Tahar Chouihed; Alexa Hollinger; Alexandre Mebazaa
Journal:  Intensive Care Med       Date:  2017-12-04       Impact factor: 17.440

5.  Time trends in characteristics, clinical course, and outcomes of 13,791 patients with acute heart failure.

Authors:  Pere Llorens; Patricia Javaloyes; Francisco Javier Martín-Sánchez; Javier Jacob; Pablo Herrero-Puente; Víctor Gil; José Manuel Garrido; Eva Salvo; Marta Fuentes; Héctor Alonso; Fernando Richard; Francisco Javier Lucas; Héctor Bueno; John Parissis; Christian E Müller; Òscar Miró
Journal:  Clin Res Cardiol       Date:  2018-05-04       Impact factor: 5.460

6.  Effect of an Emergency Department Care Bundle on 30-Day Hospital Discharge and Survival Among Elderly Patients With Acute Heart Failure: The ELISABETH Randomized Clinical Trial.

Authors:  Yonathan Freund; Marine Cachanado; Quentin Delannoy; Said Laribi; Youri Yordanov; Judith Gorlicki; Tahar Chouihed; Anne-Laure Féral-Pierssens; Jennifer Truchot; Thibaut Desmettre; Celine Occelli; Xavier Bobbia; Mehdi Khellaf; Olivier Ganansia; Jérôme Bokobza; Frédéric Balen; Sebastien Beaune; Ben Bloom; Tabassome Simon; Alexandre Mebazaa
Journal:  JAMA       Date:  2020-11-17       Impact factor: 56.272

7.  Diagnosis of acute serious illness: the role of point-of-care technologies.

Authors:  Gregory L Damhorst; Erika A Tyburski; Oliver Brand; Greg S Martin; Wilbur A Lam
Journal:  Curr Opin Biomed Eng       Date:  2019-09-16

8.  Preventable delays to intravenous furosemide administration in the emergency department prolong hospitalization for patients with acute heart failure.

Authors:  Michael J Ward; Sean P Collins; Dandan Liu; Craig M Froehle
Journal:  Int J Cardiol       Date:  2018-06-28       Impact factor: 4.164

Review 9.  Optimising Heart Failure Therapies in the Acute Setting.

Authors:  Mattia Arrigo; Petra Nijst; Alain Rudiger
Journal:  Card Fail Rev       Date:  2018-05

Review 10.  Acute heart failure.

Authors:  Mattia Arrigo; Mariell Jessup; Wilfried Mullens; Nosheen Reza; Ajay M Shah; Karen Sliwa; Alexandre Mebazaa
Journal:  Nat Rev Dis Primers       Date:  2020-03-05       Impact factor: 52.329

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.